



May 10, 2018

BSE Limited 1st Floor, P J Towers, Dalal Street,

Dalal Street, <u>Mumbai – 400 001</u>

National Stock Exchange of India Limited

Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra Kurla Complex, Bandra (East), <u>Mumbai – 400 051</u>

Re.: Press Release.

Dear Sir / Madam,

We enclose herewith a copy of press release dated May 10, 2018 titled "Zydus receives final approval from the USFDA for Carbidopa Tablets".

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.


Thanking You,

Yours faithfully, For, **CADILA HEALTHCARE LIMITED**

UPEN H. SHAH COMPANY SECRETARY

Encl.: As above





Zydus receives final approval from the USFDA for Carbidopa Tablets

Ahmedabad, 10 May, 2018

Zydus Cadila has received the final approval from the USFDA to market Carbidopa Tablets, 25 mg. It is used with a combination levodopa/carbidopa product to treat symptoms of Parkinson's disease or Parkinson-like symptoms (such as shakiness, stiffness, difficulty moving). It will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The group now has more than 190 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs over 21,000 people worldwide and is dedicated to creating healthier communities globally. Zydus aspires to be a research-based pharmaceutical company by 2020.

For further information please contact : The Corporate Communications Department Cadila Healthcare Limited 'Zydus Tower', Satellite Cross Roads, Ahmedabad 380 015. India. Phone : +91-79-2686 8100 (20 Lines) Fax : +91-79-2686 2365 www.zyduscadila.com

CIN-L24230GJ1995PLC025878